Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease
Ben Kang, So Yoon Choi, Young Ok Choi, et al.
Journal of Crohn s and Colitis (2018) Vol. 13, Iss. 2, pp. 189-197
Open Access | Times Cited: 43

Showing 26-50 of 43 citing articles:

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
Tae Jong Jeong, Eun Sil Kim, Yiyoung Kwon, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
Wan-Ting Cao, Rong Huang, Shan Liu, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 23, pp. 2582-2596
Open Access | Times Cited: 4
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Ju Young Kim, Yoon Lee, Byung‐Ho Choe, et al.
Gut and Liver (2020) Vol. 15, Iss. 4, pp. 588-598
Open Access | Times Cited: 5
Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
Yoo Min Lee, Sujin Choi, Byung‐Ho Choe, et al.
Gut and Liver (2021) Vol. 16, Iss. 1, pp. 62-70
Open Access | Times Cited: 5
The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
Junya Song, Huihui Zhang, Huihua Zhang, et al.
Pediatric Discovery (2024)
Open Access
Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
Yiyoung Kwon, Eun Sil Kim, Yoon Zi Kim, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2372-2372
Open Access | Times Cited: 3
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
Cong Dai, Min Jiang, Mingjun Sun
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 1, pp. 262-262
Open Access | Times Cited: 3
Managing pediatric Crohn’s disease: recent insights
Katherine Baldwin, Victoria Grossi, Jeffrey S. Hyams
Expert Review of Gastroenterology & Hepatology (2023) Vol. 17, Iss. 10, pp. 949-958
Closed Access | Times Cited: 1
Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels
Dong Xiang, Ninghong Li, Lu Liu, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21858-e21858
Open Access | Times Cited: 1
Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis
Anke L. Nguyen, Peter R. Gibson, Richard N. Upton, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 4, pp. 399-409
Open Access | Times Cited: 1
Early Inflammatory Markers are Associated With Inadequate Post‐Induction Infliximab Trough in Pediatric Crohn's Disease
Brad D. Constant, Salina Khushal, Jiji Jiang, et al.
Journal of Pediatric Gastroenterology and Nutrition (2020) Vol. 72, Iss. 3, pp. 410-416
Open Access | Times Cited: 3
Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review
Wan-Ting Cao, Rong Huang, Ke-Fang Jiang, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 9, pp. 886-907
Open Access | Times Cited: 3
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
Amy Hemperly, Marla C. Dubinsky, Andrés Yarur, et al.
Crohn s & Colitis 360 (2021) Vol. 3, Iss. 3
Open Access | Times Cited: 3
Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha
Manar Matar, Rachel Levi, Maya Zvuloni, et al.
Pediatric Research (2022) Vol. 93, Iss. 1, pp. 131-136
Closed Access | Times Cited: 2
Incidentally Detected Asymptomatic Perianal Abscess in an Adolescent during Crohn's Disease Diagnosis: Is Routine Pelvic Imaging Required in Korean Pediatric Patients at Diagnosis?
Soo Hyun Um, Sang Woo Lee, Ki Hwan Song, et al.
Pediatric Gastroenterology Hepatology & Nutrition (2021) Vol. 24, Iss. 6, pp. 564-564
Open Access | Times Cited: 2
The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
Wenhui Hu, Yan Feng, Ziqing Ye, et al.
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 2
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
Eric Cheah, James Guoxian Huang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 10, pp. 1395-1406
Closed Access
Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
Yoo Min Lee, Eun Sil Kim, Sujin Choi, et al.
Gut and Liver (2023) Vol. 18, Iss. 3, pp. 498-508
Open Access
Previous Page - Page 2

Scroll to top